Mineralys Therapeutics, Inc. (MLYS) Stock Price & How to Invest

Last updated November 2026

Short answer

MLYS is Mineralys Therapeutics, a clinical-stage biopharma whose entire investment case rides on one drug, lorundrostat, an aldosterone synthase inhibitor for uncontrolled and resistant hypertension that is under FDA review with a target decision date of December 22, 2026. It is a binary, event-driven biotech story: no product revenue yet, about $625 million in cash and investments, and an approval-or-not catalyst about a month away. As of November 20, 2026 the stock closed at $13.90, down about 61% year to date and about 67% over one year, for a market value near $1.2 billion, about twice its cash.

MLYS stock price

As of 2026-11-20, Mineralys Therapeutics, Inc. (MLYS) last closed at $13.66, down 67.4% over the past year. Over the past 52 weeks it has traded between $13.66 and $43.36.

MLYS last close
$13.66
1 day
-3.53%
1 month
-35.26%
1 year
-67.38%
52-week range
$13.66 to $43.36
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Mineralys Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.

MLYS key stats

At $13.66 on November 20, 2026, Mineralys Therapeutics, Inc. (MLYS) has a market cap of $1.2B.

Market cap
$1.2B
Price to book
2.4
Beta
0.82

Market cap, P/E and yield are measured at the $13.66 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Mineralys Therapeutics, Inc. (MLYS)?

The last two weeks for Mineralys Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • MLYS closed at $13.66 on November 20, 2026, down 10.9% over the past five trading days (from $15.33).

Mineralys Therapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Mineralys Therapeutics, Inc. (MLYS) do?

Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Its lead and essentially only asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being developed for uncontrolled and resistant hypertension, with additional programs exploring chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company completed its Phase 3 program (including the Launch-HTN and Advance-HTN trials) and submitted a New Drug Application that the FDA accepted, with a PDUFA target action date of December 22, 2026. As of its August update, commercial leadership was in place, initial sales territories had been identified, and the company expected its sales force to be built before that date.

The investment picture is that of a classic binary biotech. As a pre-revenue company, Mineralys reported a net loss of about $241 million in Q2 2026, mostly a one-time $200 million payment to Tanabe Pharma that eliminated future royalties on lorundrostat (up to $255 million of commercial milestones remain). In the same quarter it raised about $150 million in a follow-on offering and drew $100 million of a term loan facility of up to $500 million from Pharmakon. Cash and investments stood at about $661 million on June 30, 2026 and about $624.7 million on September 30, which management expects to fund operations, including the launch, into 2028. The third-quarter net loss was about $57.3 million, or $0.64 a share against a $0.54 consensus, as general and administrative costs rose to about $37.4 million with launch hiring and professional fees. The November 4 release said the FDA continues its review with the December 22 target date unchanged. On November 8 Mineralys presented late-breaking long-term Transform-HTN open-label extension data at the AHA Scientific Sessions, and the stock rose the next trading day, but UBS cut its target to $19 from $29 with a neutral rating. The stock, valued near $1.2 billion on November 20, 2026 after a roughly 61% slide this year, still prices in a meaningful probability of approval and commercial success in a very large hypertension market. The flip side is concentration risk: a negative FDA decision, a competitive setback, or a disappointing launch would weigh heavily because there is no diversified pipeline or product revenue to cushion it.

What's driving Mineralys Therapeutics, Inc. (MLYS)?

1. Lorundrostat FDA decision

The single largest driver is the FDA review of lorundrostat for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026. An approval would move Mineralys from clinical-stage to a commercial-stage company with a first-in-class-tier aldosterone synthase inhibitor. The decision is the defining catalyst for the stock, now about a month out, and the company's November 4 update said the review was continuing with no change to the date.

2. Large uncontrolled-hypertension market

Uncontrolled and resistant hypertension affects a very large patient population that remains poorly served by existing generic therapies. Lorundrostat targets aldosterone, a hormone implicated in blood pressure that current standard regimens do not directly address. Consensus models about $75 million of revenue in 2027, the first full year after a potential approval. With the Tanabe royalty gone, more of each sales dollar would stay with Mineralys.

3. Pipeline expansion into CKD and OSA

Beyond core hypertension, Mineralys is studying lorundrostat in chronic kidney disease and obstructive sleep apnea, conditions where aldosterone dysregulation plays a role. In October 2026 it presented new data at the American Heart Association Hypertension Scientific Sessions and announced presentations at the American Society of Nephrology Kidney Week, and on November 8, 2026 it presented long-term Transform-HTN open-label extension data as a late-breaker at the AHA Scientific Sessions, showing sustained blood pressure reductions. The Phase 2 Explore-CKD results were published in Kidney International in late October.

4. Balance sheet and launch readiness

With about $624.7 million in cash and investments at September 30, 2026 and runway guided into 2028, Mineralys has capital to fund a launch without immediate financing pressure. That cushion came partly from a June 2026 equity raise of about $150 million (dilutive to holders) and a $100 million loan draw, with up to $400 million more available under the Pharmakon facility. A new Chief Medical Officer, Dr. Terry Ferguson (ex-Amgen, AstraZeneca), joined in August, and by November the company reported an expanded medical affairs team and sales force, brand marketing underway and a patient support program being finalized. Interest on the term loan cost about $3.2 million in the third quarter.

What are the risks to Mineralys Therapeutics, Inc. (MLYS)?

The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash, has raised equity, and now carries about $98 million of debt, creating dilution and leverage risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to regulatory news: it fell about 32% in the month to November 20, 2026 and closed at $13.90, near its 52-week low of about $13.58, against a high of about $44.13.

What is the Mineralys Therapeutics, Inc. (MLYS) forecast?

9 analysts publish price targets on MLYS, averaging $43.56 as of November 2026, or +218.9% against the $13.66 share price on November 20, 2026. The published targets run from $19.00 to $56.00, a wide spread, and the ratings split 9 buy, 2 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MLYS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is MLYS a buy or a sell?

We give no verdict on Mineralys Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Lorundrostat FDA decision. The single largest driver is the FDA review of lorundrostat for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026. The most optimistic published target, $56.00, assumes this works close to its best case.

The case against. The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. The most pessimistic target, $19.00, is roughly what MLYS is worth if this bites instead.

Read the full bull and bear case on MLYS, including what would have to change to break either one. Walnut is not an investment adviser.

Has Mineralys Therapeutics, Inc. (MLYS) split its stock?

No. Mineralys Therapeutics, Inc. (MLYS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Mineralys Therapeutics, Inc. (MLYS) valued?

Market cap, P/E and dividend yield at today's price are in the MLYS key stats above. The business figures below come from Mineralys Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.

  • Product revenue (TTM): ~$0 (pre-commercial)
  • Cash & investments: ~$624.7M (September 30, 2026); runway guided into 2028
  • Q3 2026 net loss: ~$57.3M; EPS -$0.64 vs ~-$0.54 consensus
  • Q3 2026 operating costs: R&D ~$22.7M; G&A ~$37.4M (up from ~$9.7M on launch build)
  • Net loss (TTM): ~$370M, incl. $200M Tanabe royalty buyout; EPS about -$4.30
  • Debt: ~$98M (Pharmakon term loan, up to $500M facility)

As of November 2026: Standard valuation multiples do not apply to Mineralys because it has no product revenue and posts ongoing losses funded by its cash balance. The roughly $1.2 billion market value, about 2 times its cash, down from about 2.8 times in October, reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing fundamentals. The nine covering analysts rate it a strong buy with a mean target near $44, about three times the current price, though UBS cut its target to $19 in November, so the spread of views ahead of the December 22 decision is wide.

Who competes with Mineralys Therapeutics, Inc. (MLYS)?

Aldosterone synthase inhibitor developers

The most direct competitor is AstraZeneca, whose baxdrostat is a late-stage aldosterone synthase inhibitor with strong Phase 3 hypertension data and far greater commercial scale. Other emerging candidates in this class (such as vicadrostat, tied to Boehringer Ingelheim, and dexfadrostat) compete for the same aldosterone-driven mechanism, making the class race a central dynamic for Mineralys.

Established hypertension therapies

Lorundrostat would launch into a market dominated by inexpensive generic antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, diuretics) and mineralocorticoid receptor antagonists like spironolactone. These low-cost incumbents set the bar for payer coverage and physician adoption that any new branded therapy must clear.

Large-cap cardiovascular pharma

Big pharmaceutical companies with cardiovascular and renal franchises (including firms developing therapies for CKD and heart failure) represent both competition for prescriber attention and potential acquirers or partners. Their scale in sales, trials, and payer negotiation contrasts with Mineralys's single-asset, clinical-stage profile.

What stocks are similar to Mineralys Therapeutics, Inc. (MLYS)?

Other names that sit close to MLYS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Mineralys Therapeutics, Inc. (MLYS)

There are three common ways to get MLYS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MLYS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MLYS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Mineralys Therapeutics, Inc. (MLYS)

MLYS is a pre-commercial, single-asset hypertension biotech where the FDA decision on lorundrostat (due December 22, 2026) and its eventual launch, not current financials, define the outcome. In 2026 the company bought out its royalty to Tanabe, added a $500 million loan facility and built a sales team, while the share price fell about 61% to $13.90 by November 20, including about 32% in the last month, even as the FDA review continued on schedule and new long-term data were presented at AHA.

More on Mineralys Therapeutics, Inc. (MLYS)

Whether MLYS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MLYS a buy or a sell?, and where the stock could go from here in the MLYS stock forecast.

For income investors, whether MLYS pays a dividend and how the payout looks is covered in does MLYS pay a dividend? And to weigh MLYS against a peer, read the full side-by-side comparisons: MLYS vs AZN and MLYS vs MRNA.

Wondering how MLYS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Mineralys Therapeutics, Inc.

Ask Walnut's AI anything about MLYS and see how it fits what you own.

FAQ

What does Mineralys Therapeutics (MLYS) do?

+

Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension, with additional research in chronic kidney disease and obstructive sleep apnea. It is based in Radnor, Pennsylvania, and had 76 employees as it built out a sales organization ahead of a potential approval.

Does MLYS have any approved products or revenue?

+

No. As of November 2026 Mineralys has no approved products and no product revenue. It is pre-commercial, funding operations from its cash balance while its lead drug lorundrostat is under FDA review. Analysts expect the first sales in 2027 if the drug is approved.

What is the FDA decision date for lorundrostat?

+

The FDA accepted the lorundrostat New Drug Application and set a PDUFA target action date of December 22, 2026. That decision is the single most important near-term event for the company and the stock. The company said in its November 4, 2026 update that the FDA continues its review, with no change to the date, and that launch preparations, including the sales force, were well advanced.

How much cash does Mineralys have?

+

Mineralys reported about $624.7 million in cash and investments as of September 30, 2026, against about $98 million of debt, and management has guided that this funds operations, including a lorundrostat launch, into 2028. In June 2026 it raised about $150 million in a stock offering and drew $100 million of a term loan facility of up to $500 million.

Who are MLYS's main competitors?

+

The most direct competitor is AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor. Broader competition comes from cheap generic antihypertensives and mineralocorticoid receptor antagonists like spironolactone that dominate current hypertension treatment.

Why is MLYS considered a high-risk stock?

+

The company's value depends almost entirely on one drug, lorundrostat. A negative FDA decision, safety issue, competitive setback, or weak launch would hit hard because there is no product revenue or diversified pipeline to offset it. The stock is highly volatile: it lost about 32% in the month to November 20, 2026 and about 61% year to date.

How is MLYS valued if it has no revenue?

+

Its roughly $1.2 billion market value (November 2026) reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing earnings or revenue. Traditional multiples like price-to-earnings do not apply to a pre-revenue biotech; the stock trades at about 2 times its cash balance.

What is lorundrostat's addressable market?

+

Lorundrostat targets uncontrolled and resistant hypertension, a very large patient population poorly served by existing generics, plus potential expansion into chronic kidney disease and obstructive sleep apnea. The size of that opportunity, weighed against approval and adoption risk, drives the investment debate.

How did Mineralys do in its latest quarter?

+

For Q3 2026 (reported November 4), Mineralys posted a net loss of about $57.3 million, or $0.64 per share, against a consensus of about $0.54. R&D fell to about $22.7 million as the Phase 3 program wound down, while G&A rose to about $37.4 million on launch hiring and professional fees. Cash and investments were about $624.7 million at September 30. The prior quarter's $2.85 loss per share was driven by the one-time $200 million Tanabe royalty buyout. Consensus for the fourth quarter is a loss near $0.68 per share.

How has MLYS stock performed in 2026?

+

As of November 20, 2026, MLYS closed at $13.90, down about 61% year to date and about 67% over the past year, near the bottom of its 52-week range of about $13.58 to $44.13. It fell about 32% in the final month alone, despite an on-schedule FDA review and new long-term lorundrostat data at AHA in November, and ahead of the December 22 FDA decision. Walnut is not an investment adviser and does not predict regulatory outcomes.

What was the Tanabe royalty buyout?

+

In June 2026 Mineralys amended its license with Tanabe Pharma, which originally licensed lorundrostat to it, paying $200 million upfront to eliminate future royalties on sales. It still owes up to $255 million in commercial milestones tied to first sale and annual sales targets, plus up to $10 million for a second indication, and Tanabe agreed to assign the underlying intellectual property to Mineralys.

What did the Transform-HTN data at AHA 2026 show?

+

On November 8, 2026 Mineralys presented late-breaking data from the Transform-HTN open-label extension trial of lorundrostat at the American Heart Association Scientific Sessions. The company described sustained blood pressure reductions with longer-term dosing, and the stock rose the following trading day. Long-term durability matters for a chronic therapy, since hypertension patients stay on treatment for years.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Mineralys Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.